Barclays just hosted its 2017 Eat, Sleep, Play Conference, focusing in on a number of restaurant players. Jeffrey Bernstein, Senior Restaurant Analyst at Barclays was with us to discuss the biggest takeaways from the event.
Despite believing that Shake Shack is head of the class in the better-burger category, Bernstein is maintaining his "Equal Weight" rating for the stock. The analyst points to the fact its shares trade at much higher valuations than its peers. However, he says this is mostly justified because of the rate Shake Shack is opening up stores and growing revenue.
Bernstein also touches on Domino's Pizza and how the chain stacks up against Papa John's and Pizza Hut. Recently, Papa John's said sales were impacted by the kneeling in the NFL. Bernstein says Domino’s was not willing to make a comment like that. He adds Domino's is still bullish on advertising in big sports events because it is still generating a return for them. They are, however, starting to do a lot more online marketing, says Bernstein.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
